INNER-CITY ANTI-IGE THERAPY FOR ASTHMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 内城哮喘抗IGE疗法研究是一项随机、双盲、安慰剂对照、平行分组的疗效和安全性试验，旨在比较250名内城6-20岁患有中到重度过敏性哮喘的儿童和青少年接受标准化护理(包括基本哮喘教育)的情况，以及250名类似的儿童和青少年接受Xolair类似的标准化专科护理和治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Inner-City Anti-IGE Therapy for Asthma study is a randomized, double-blind, placebo-controlled, parallel group efficacy and safety trial designed to compare 250 inner-city children and adolescents age 6-20 years old with moderate-to-severe allergic asthma receiving standardized care, including basic asthma education, with 250 similar children and adolescents receiving comparable standardized specialist care and treatment with Xolair.